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Abstract
Background: Metastatic melanoma (mM) and renal cell carcinoma (mRCC) are often treated with anti-PD-1 based
therapy, however not all patients respond and further therapies are needed. High dose interleukin-2 (HD IL-2) can
lead to durable responses in a subset of mM and mRCC patients. The efficacy and toxicity of HD IL-2 therapy
following anti-PD-1 or anti-PD-L1 therapy have not yet been explored.
Methods: Reports on mM and mRCC patients who had received HD IL-2 after PD-1 or PD-L1 inhibition were
queried from the PROCLAIMSM database. Patient characteristics, toxicity and efficacy were analyzed.
Results: A total of 57 patients (40 mM, 17 mRCC) were treated with high dose IL-2 after PD-1 or PD-L1 inhibition
and had data recorded in the PROCLAIM database. The best overall response rate to HD IL-2 was 22.5% for mM (4
complete response (CR), 5 partial responses (PRs)) and 24% for mRCC (2 CRs, 2 PRs). The toxicity related to HD IL-2
observed in these patients was similar to that observed in patients treated with HD IL-2 without prior checkpoint
blockade. One patient who had received prior PD-L1 blockade developed drug induced pneumonitis with HD IL-2
requiring steroid therapy.
Conclusion: In this retrospective analysis, HD IL-2 therapy displayed durable antitumor activity in mM and mRCC
patients who progressed following treatment with PD-1 and PD-L1 inhibition. The toxicities were generally
manageable and consistent with expectations from HD IL-2 but physicians should watch for immune related
toxicities such as pneumonitis. This analysis supports the development of randomized prospective trials to assess
the proper sequencing and combination of immune checkpoint blockade and cytokine therapy.
Background
Immunotherapy is rapidly expanding into the treatment
of numerous malignancies. One of the earliest immuno-
therapies, high dose interleukin-2 (HD IL-2), activates
T-cells and has documented durable tumor responses in
a subset of patients with mM and mRCC. [1–3] How-
ever, the acute toxicity profile and requirement for in-
tensive inpatient management have limited the
application of HD IL-2, and immune checkpoint block-
ade (ICB) has largely replaced it as a frontline treatment
of advanced mM and mRCC. [4]
Ipilimumab, has proven benefit in metastatic melan-
oma (mM) as a single agent and now in combination
with other immunotherapy agents. PD-1 inhibition with
nivolumab or pembrolizumab has been even more ef-
fective leading to FDA approval in mM, renal cell car-
cinoma (mRCC), and several other malignancies. [5–10]
However, alternative therapies are needed for patients
who develop severe side effects, progress after an initial
response or fail to respond to ICB.
The field is plentiful with clinical trials of novel agents
targeting immune checkpoints, injectable therapies such
as anti-tumor viruses, T-cell based therapies including
TIL (Tumor infiltrating lymphocyte) and CAR-T cells
(Chimeric antigen receptor T-cells) alone and in
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combination. With this explosion of interest in immuno-
therapy, there has been renewed interest in cytokines
and their role in immune stimulation and overcoming
resistance to checkpoint inhibition. Novel drugs target-
ing the IL-2 receptor are in clinical trials.
The field of immunotherapy is now tasked with find-
ing appropriate treatments for patients who do not
benefit from ICB. Clinical trials involving single agents
and combinations require hypothesis-generating data as
well as clinical experience to help guide progress in this
area.
In this study, we queried the PROCLAIM database for
patients with mM or mRCC who had developed resist-
ance to PD-1/PD-L1 inhibition and were subsequently
treated with HD IL-2 to examine its efficacy, toxicity
and long-term outcomes in the salvage setting. We also
queried the database for patients treated with HD IL-2
who did not receive prior PD-1 or PD-L1 inhibition as a
comparator group.
Methods
Patients
The PROCLAIM registry is a database of patients, from
more than 40 community and large academic centers,
who received HD IL-2 in the treatment of mM or mRCC
(Clinicaltrials.gov: NCT 01415167) The study was ap-
proved by the institutional review boards of the sites en-
rolling subjects and all patients provided written,
informed consent. For this study, the registry was quer-
ied to identify patients treated with HD IL-2 prior to or
following PD-1 or PD-L1 inhibition. Patient characteris-
tics, including age, gender, disease type, number and
type of prior therapies and prior responses to therapy by
treating physician assessment were analyzed. In addition,
the IL-2 dosing, response and toxicity were reported.
Treatment
HD IL-2 was administered per the treating institution’s
standard of care as an inpatient regimen, typically utiliz-
ing a 600,000 IU/kg or 720,000 IU/kg IV infusion every
8 h as tolerated up to 14 consecutive doses over 5 days.
The database captured up to 3 toxicities leading to dis-
continuation of IL-2 per patient. Those patients who
were admitted for a second week/cycle of treatment,
returned after approximately 9 days off therapy. Two
weeks of HD IL-2 therapy constituted one course of
treatment. Some patients received additional courses of
therapy per the treating physician’s discretion.
Response data and toxicity
The number of patients who achieved a complete re-
sponse (CR), partial responses (PR), stable disease (SD)
and progressive disease (PD) at initial assessment follow-
ing HD IL-2, as determined by the treating physician
using RECIST 1.1 is reported. In addition, best overall
response, objective response rate (ORR) and median
overall survival (OS) are also reported. The best overall
response is the best response recorded from the start of
HD IL-2 treatment until disease progression/recurrence
or initiation of a new anti-cancer therapy. Response and
survival endpoints were measured from the start of HD
IL-2 therapy and were compared amongst patients who
did and those who did not receive prior PD-1 or PD-L1
therapy. Toxicities, and immune related toxicities, were
examined in patients who received IL-2 after PD-1 or
PD-L1 inhibition and compared to subjects who received
HD IL-2 without prior ICB.
Statistical analysis
All statistical analyses were performed using SAS soft-
ware version 9.4 (SAS Institute, Cary, NC). Frequency
counts and measures of central tendency were per-
formed to provide descriptive statistics; medians were
reported with the minimum and maximum values.
Kaplan-Meier curves with 95% confidence intervals (CIs)
were used to estimate median overall survival (mOS)
and progression free survival (PFS). Overall survival time
was calculated from the date of first dose of HD IL-2 to
either the date of death or date of most recent
follow-up. PFS was calculated from the date of first dose
of HD IL-2 to the date of mM or mRCC progression or
start of a new anti-cancer treatment.
Results
Patient characteristics
A total of 57 patients (40 mM, 17 mRCC) were identified
within the PROCLAIM registry who had received high
dose IL-2 following treatment with PD-1 or PD-L1 in-
hibition. Another 1122 mM and mRCC patients were
identified within the registry who were treated with HD
IL-2 without prior ICB.
Among the mM patients, 18 received PD-1 inhibition
with nivolumab, 17 with pembrolizumab, and the re-
mainder received PD-1 inhibition without identification
of the drug. Four mM patients received combination
nivolumab and ipilimumab. Among the mRCC patients
8 received PD-1 inhibition with nivolumab and 1 re-
ceived pembrolizumab. Three mRCC patients received
PD-L1 inhibition with atezolizumab and the remainder
received PD-1 inhibition without identification of the
drug. Patients may have received more than one PD-1 or
PD-L1 targeted agent. Patients were predominantly male
with ECOG performance status of 0 or 1 and had greater
than or equal to 3 sites of metastatic disease (Additional file 1:
Table S1). The mean LDH was 336.5 (117–904) in the
mM patients.
Mutational status was reported for 25% of all 40 mM
patients. Among those patients in whom mutational
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status was reported, 4 were noted to be BRAF mutant, 5
were noted to be NRAS mutant and one had a cKIT
mutation. Among the mM patients, seven had prior
BRAF inhibitor therapy. Among the mRCC patients, six
had prior anti-VEGF tyrosine kinase inhibitor therapy.
The mean time between diagnosis of metastatic dis-
ease and initiation of HD IL-2 was 22.4 (0.8–55.8)
months for the mM patients and 31.8 (0.2–156.0)
months for the mRCC patients. The average treatment
duration for HD IL-2 (including rest periods) was 2.1
(0.1–7.3) months in the mM patients and 1.8 (0.1–6.1)
in the mRCC patients. All patients had progression of
their disease prior to initiating treatment with HD IL-2.
The average time between completing PD-1/PD-L1
therapy and starting HD IL-2 was 6.3 (0.3–28.1) months
for the mM patients, and 2.1 (0.4–7.4) months for the
mRCC patients. On average mM patients were on PD-1/
PD-L1 therapy for a mean of 5.4 (1.5–27.5) months and
9.3 (0.7–31.2) months in the mRCC patients. In mM pa-
tients, investigator reported response data to PD-1/
PD-L1 therapy was available for 29 patients, all of whom
had PD. Among the mRCC patients, investigator re-
ported response data to PD-1/PD-L1 therapy was avail-
able for 12 patients, one patient had an initial PR but
eventually progressed and 11 patients had PD.
Toxicity
Adverse events reported prior to initiation of HD IL-2
include one mM patient and one mRCC with elevated
liver function testing prior to initiation of HD IL-2. Prior
toxicity to PD-1 and PD-L1 was recorded retrospectively
so some of the data may be lacking.
Hypotension was the most common toxicity reported
which resulted in the cessation of HD IL-2. Other re-
corded toxicities include tachycardia, diarrhea, hypoxia,
thrombocytopenia, rigors, capillary leak syndrome, con-
fusion, mental fatigue and pruritus. These toxicities
are consistent with those observed with HD IL-2.
(Additional file 2: Table S2).
The average number of HD IL-2 doses per cycle is
often used as a reflection of toxicity since IL-2 is held
when a patient is having more severe side effects. A
course of high dose IL-2 therapy consists of two cycles.
The mM patients received an average of 8.1 (SD 2.4)
doses of IL-2 per cycle. The mRCC patients received an
average of 8.0 (SD 3.0) doses of IL-2 per cycle. Among
the mM patients for whom cycle data was available, 20%
received one cycle, 27.5% received two cycles, 7.5% re-
ceived 3 cycles, 22.5% received 4 cycles and 12.5% re-
ceived more than 4 cycles. In the mRCC patient cohort
for whom cycle data was available 12% received one
cycle, 35% received 2 cycles, 29% received four cycles
and 12% received more than 4 cycles. (Additional file 3:
Table S3).
The database reported no autoimmune toxicities in
any of the patients receiving HD IL-2 following PD-1 or
PD-L1 inhibition. However, one of the institutions re-
ported a patient with presumed, severe pneumonitis dur-
ing HD IL-2 therapy that was felt to be related to prior
PD-L1 inhibition. This patient had no prior irAEs to
PD-L1 inhibition. On treatment day 7, after receiving 11
of a possible 14 HD IL-2 doses, he developed shortness
of breath and hypoxia with an oxygen saturation of 88%.
Initial imaging was consistent with pulmonary edema
from HD IL-2 induced capillary leak, however his condi-
tion did not improve with diuresis and repeat imaging
showed worsening pulmonary infiltrates suggestive of
pneumonitis. He was treated with intravenous methylpred-
nisolone to treat presumed immune related pneumonitis
and had marked improvement in symptoms, oxygen satur-
ation and imaging. He subsequently underwent a steroid
taper with continued improvement in symptoms.
Response rates and survival
The median follow up of all patients following HD IL-2
treatment was 11.2 (0.3–30.9) months for the mM group
and 11.3 (0.6–29.0) months for the mRCC group. Of the
patients previously treated with PD-1/PD-L1 inhibition,
the best overall response reported to HD IL-2 was
23% (23% in mM and 24% in mRCC) with 6 patients (4
mM and 2 mRCC) experiencing a complete response
(CR) and 7 patients (5 mM and 2 mRCC) experiencing a
partial response (PR). 38% of the mM patients and 47%
of the mRCC patients had stable disease. Response data
is summarized in Table 1. None of the melanoma pa-
tients who had a CR had progressed at the time of the
database lock, 1–4 years of follow up. 3/5 PRs in melan-
oma were continuing as of the database lock, 1–2 years
of follow up. None of the two mRCC patients who had a
CR progressed, over two years of follow up. Neither of
the two mRCC patients with a PR progressed, over two
years of follow up.
The median overall survival for mM patients with
prior ICB, measured from the initiation of HD IL-2
Table 1 Best Response to HD IL-2
Type Best Response mM
(N = 40)
mRCC
(N = 17)
Initial Response Complete Response 0 (0) 1 (6)
Partial Response 3 (8) 1 (6)
Stable Disease 20 (50) 9 (53)
Progressive Disease 17 (42) 6 (35)
Best Overall Response Complete Response 4 (10) 2 (12)
Partial Response 5 (13) 2 (12)
Stable Disease 15 (37) 8 (47)
Progressive Disease 16 (40) 5 (29)
Buchbinder et al. Journal for ImmunoTherapy of Cancer            (2019) 7:49 Page 3 of 7
administration, was 29.4 months as compared to 15.3
months in the HD IL-2 alone group. The median
overall survival for mRCC patients with prior ICB
was not reached as compared to 40.8 months in the
HD IL-2 alone group. The median progression free
survival in the mM group was 3.5 months as com-
pared to 2.8 months in the HD-IL2 alone group and
was 8.6 months in the mRCC group as compared to
13months in the HD IL-2 alone group. Representative
curves comparing the two groups are presented in
Figs. 1 and 2.
Discussion
In this analysis, we examined the response and toxicity
patterns of patients previously treated with PD-1 or
PD-L1 inhibition who then received HD IL-2. We ob-
served a response rate to HD IL-2 consistent with that
observed in patients who had not been previously
treated with ICB. Although the study cohort in this re-
port is small, the data suggests that HD IL-2 is a viable
option for patients who have progressed after ICB. In
fact, the overall survival data was very similar for pa-
tients who previously received PD-1 or PD-L1 inhibition
a)
b)
Fig. 1 Overall Survival in months for patients treated with IL-2 alone or IL-2 following PD-1 inhibition in metastatic melanoma (a) and metastatic
renal cell carcinoma (b)
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as those who did not. Since these patients were more
heavily pre-treated it is encouraging that these outcomes
were similar although there is concern that we are
selecting for patients with more slowly progressive dis-
ease able to receive multiple treatments.
The success of PD-1 and PD-L1 inhibition in oncology
is expanding opportunities to explore combination im-
munotherapy. HD IL-2 is an attractive target for such
exploration since it is a therapy that has documented,
single agent anti-tumor efficacy and prolonged duration
of responses and survival. [3] In addition, many oncolo-
gists already have extensive experience with high dose
IL-2 allowing for it to be given safely in the appropriate
setting. When studied in a mouse model of chronic
lymphocytic choriomeningitis virus it was observed that
PD-L1 blockade synergizes with IL-2 therapy to enhance
CD8+ T cell responses and decrease viral load. [11] In
addition a report of 36 patients who received ipilimumab
with IL-2 demonstrated a 17% complete response rate
and manageable toxicity. [12]
Experience has demonstrated that combination im-
munotherapies can have marked increased toxicity as
observed with combination ipilimumab and nivolumab
[8]. In addition, an increase in toxicity was observed
a)
b)
Fig. 2 Progression-Free Survival in months for patients treated with IL-2 alone or IL-2 following PD-1 inhibition in metastatic melanoma (a) and
metastatic renal cell carcinoma (b)
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when ipilimumab and nivolumab therapies were se-
quenced in mM patients suggesting residual effects from
prior immunotherapy. [13] [14] In this analysis, there
was no obvious trend towards increased toxicity in the
group of patients who received HD IL-2 after PD-1 or
PD-L1 inhibition. However, there was a case report of a
patient with presumed IL-2 induced pneumonitis that
required steroid therapy. Pneumonitis during HD IL-2
has not been previously reported. HD IL-2 leads to in-
creased cytokine production leading to T-cell stimula-
tion. In a case of indolent pneumonitis where there are
already immune infiltrates within the lung, it is possible
that there may be a recall exacerbation when anti-PD1
therapy is followed by HD IL-2. Due to the retrospective
nature of this database an analysis such as this might
miss other important immune related toxicities that
were less severe but clinically important.
One of the potential factors that may be limiting HD
IL-2 efficacy is its often-competing actions maintaining
T regulatory cells in addition to CD8+ T cells an NK
cells that target tumors. Attempts to overcome this have
led to the development of novel compounds targeting
subunits of the IL-2 receptor. The IL-2 receptor consists
of 3 components an α chain, β chain and γ chain with
stimulation through βγ leading to stimulation of an im-
mune response and stimulation through αβγ leading to
immune suppression [15]. A novel compound which tar-
gets the IL-2Rβγ is NKTR-214 which is being tested
alone and in combination with ICB (NCT02869295,
NCT02983045, NCT03138889). ALKS 4230 is a fusion
protein of circularly permuted IL-2 and a soluble portion
of IL-2Rα to prevent signaling through IL-2Rα which is
also in clinical testing (NCT02799095). Also in clinical
testing are FAP-IL-2v and CEA-IL2v, IL-2 variant based
immunocytokines (NCT02350673).
These data support continued exploration of HD IL-2 as
an immunotherapy in patients with mM and mRCC. There
does not appear to be a detrimental outcome for the se-
quential use of HD IL-2 following anti-PD-1 therapy, and
ORR is at least comparable to studies of IL-2 alone. There
are currently several studies combining ICB with HD IL-2
including two in mRCC (NCT02989714, NCT0296078)
and one in mM (NCT02748564). In addition, studies of
novel compounds targeting IL-2 are an important addition
to our current exploration of immunotherapy and will build
on our understanding of immune signaling.
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